{"title":"Biochemical Meaning of Defective Immune:Surveillance in Cancer Patients","authors":"Tsuneo Kobayashi","doi":"10.21767/2254-6081.100174","DOIUrl":null,"url":null,"abstract":"Background: For a long time, phenomenon of defective immune-surveillance in cancer patients from pathological standpoint was not elucidated. I have reported 1985 that lowering seral cyclic AMP is biochemical reason of defective immunesurveillance from adoptive lymphocyte immunotherapy experiment among cancer patients. Recently, Honjo Tasku et al., reported why T cell don’t attack cancer cells by the covering of PD-L1 on its receptor of PD-1. This is also one of defective immune-surveillance from cellular side. I have recently surveyed the correlation between seral cyclic AMP concentration and immune activity in cancer patients. I have confirmed the biochemical reason of lowering cyclic AMP leads to seral defective immune-surveillance in cancer patient’s serum. Methods: I have surveyed seral cyclic AMP concentration and T cell number and NK cell among 40 cancer patients and preclinical cancer patients. Results: The averaged seral cyclic AMP has a positive tendency between lower immune activity and lower cyclic AMP in the serum when cancer is developing beforehand. Conclusion: As cyclic AMP is elevated after fasting therapy, adoptive lymphocyte immunotherapy become useful as immuno-potentiation even if in advanced cancer patients.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100174","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives in cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21767/2254-6081.100174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: For a long time, phenomenon of defective immune-surveillance in cancer patients from pathological standpoint was not elucidated. I have reported 1985 that lowering seral cyclic AMP is biochemical reason of defective immunesurveillance from adoptive lymphocyte immunotherapy experiment among cancer patients. Recently, Honjo Tasku et al., reported why T cell don’t attack cancer cells by the covering of PD-L1 on its receptor of PD-1. This is also one of defective immune-surveillance from cellular side. I have recently surveyed the correlation between seral cyclic AMP concentration and immune activity in cancer patients. I have confirmed the biochemical reason of lowering cyclic AMP leads to seral defective immune-surveillance in cancer patient’s serum. Methods: I have surveyed seral cyclic AMP concentration and T cell number and NK cell among 40 cancer patients and preclinical cancer patients. Results: The averaged seral cyclic AMP has a positive tendency between lower immune activity and lower cyclic AMP in the serum when cancer is developing beforehand. Conclusion: As cyclic AMP is elevated after fasting therapy, adoptive lymphocyte immunotherapy become useful as immuno-potentiation even if in advanced cancer patients.